智通财经APP讯,珍宝岛(603567.SH)公告,公司收到国家药品监督管理局颁发的《药物临床试验批准通知书》,药品名称为:复方芩兰口服液,审批结论为: 2025年3月13日受理的复方芩兰口服液(CYZB2500437)临床试验申请符合药品注册的有关要求,在进一步完善临床试验方案的基础上,同意本品开展用于4-12岁儿童外感风热的临床试验。
智通财经APP讯,珍宝岛(603567.SH)公告,公司收到国家药品监督管理局颁发的《药物临床试验批准通知书》,药品名称为:复方芩兰口服液,审批结论为: 2025年3月13日受理的复方芩兰口服液(CYZB2500437)临床试验申请符合药品注册的有关要求,在进一步完善临床试验方案的基础上,同意本品开展用于4-12岁儿童外感风热的临床试验。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.